1,366 Shares in Axon Enterprise, Inc $AXON Acquired by Fieldview Capital Management LLC

Fieldview Capital Management LLC acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,366 shares of the biotechnology company’s stock, valued at approximately $776,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the last quarter. Geode Capital Management LLC raised its holdings in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares during the last quarter. Baillie Gifford & Co. raised its holdings in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares during the last quarter. Edgewood Management LLC purchased a new position in Axon Enterprise in the 4th quarter worth approximately $846,516,000. Finally, Norges Bank purchased a new position in Axon Enterprise in the 4th quarter worth approximately $515,764,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 0.3%

Shares of AXON stock opened at $443.21 on Tuesday. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The firm has a fifty day moving average price of $410.95 and a 200-day moving average price of $488.34. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The company has a market cap of $35.72 billion, a price-to-earnings ratio of 178.00, a PEG ratio of 8.03 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.Axon Enterprise’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.47 EPS. As a group, equities analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research reports. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Piper Sandler reiterated an “overweight” rating and set a $674.00 target price on shares of Axon Enterprise in a research note on Monday. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares of the company’s stock, valued at $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $10,000,000.00. Following the sale, the chief executive officer directly owned 3,060,997 shares in the company, valued at approximately $1,530,498,500. This represents a 0.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 38,989 shares of company stock valued at $19,090,083. 4.20% of the stock is currently owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.